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Background:  The  live  measles  vaccine  has  been  associated  with  lower  non-measles  mortality  and  admis-
sions  in  low-income  countries.  The  live measles–mumps–rubella  vaccine  has  also  been  associated  with
lower  rate  of  admissions  with  any  type  of  infection  in  Danish  children;  the  association  was  strongest  for
admissions  with  lower  respiratory  infections.
Objective: To  examine  whether  measles,  mumps,  and  rubella  (MMR)  vaccination  was  associated  with
reduced  rate of  hospital  contact  related  to  respiratory  syncytial  virus  (RSV)  in  a high-income  country.
Methods:  Nationwide  cohort  study  of laboratory-conﬁrmed  RSV  hospital  contacts  at age  14–23 months
in  all  children  born  in  Denmark  1997–2002  who  had  already  received  the  vaccine  against  diphtheria,
tetanus,  pertussis  (acellular),  polio,  and  Haemophilus  inﬂuenzae  type b  (DTaP-IPV-Hib)  at  the  recom-
mended  ages  of 3, 5, and  12 months.
Results:  The  study  included  888  RSV  hospital  contacts  in  128,588  person  years  of  follow  up (rate  6.8/1000
person  years).  Having  MMR  as  the most  recent  vaccine  was  associated  with  a reduced  rate  of  RSV  hospital
contacts compared  with  having  DTaP-IPV-Hib  as  the  most  recent  vaccine  (Incidence  rate  ratio  (IRR),  0.75;
95% conﬁdence  interval  (CI),  0.63–0.89).  After  adjustment  for potential  confounders  including  exact  age
in  days  the IRR was  0.78 (95%  CI,  0.66–0.93).  The  adjusted  IRR was  0.74  (95%  CI,  0.60–0.92)  in males  and
0.84  (95% CI, 0.66–1.06)  in females  (P  Interaction,  0.42).  There  was  no association  in the  ﬁrst  month  after
MMR  vaccination  (adjusted  IRR,  0.97;  95% CI, 0.76–1.24)  but  the adjusted  IRR  was  0.70 (95%  CI,  0.58–0.85)
from  one  month  after  MMR  vaccination.
Conclusions:  MMR  vaccination  was  associated  with  reduced  rate  of  hospital  contacts  related  to  laboratory-
conﬁrmed  RSV  infection.  Further  research  on the  association  between  MMR  vaccination  and  other
unrelated  pathogens  are  warranted.
ublis© 2014  The  Authors.  P
. Introduction
Besides the disease-targeted effects, vaccines may  affect mor-
idity and mortality to unrelated infections by changing the
eneral level of resistance toward infections, the so-called non-
peciﬁc effects of vaccines [1–3]. In low-income countries, live
Abbreviations: CI, Conﬁdence interval; DTaP-IPV-Hib, Inactivated vaccine
gainst diphtheria, tetanus, pertussis (acellular), polio, and Haemophilus inﬂuenzae
ype b; GP, general practitioner; IRR, incidence rate ratio; MMR, Live vaccine against
easles, mumps, and rubella; OPV, Oral polio vaccine; RSV, Respiratory syncytial
irus.
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
vaccines like bacille Calmette–Guérin (BCG) against tubercu-
losis and measles vaccine have beneﬁcial effects on all-cause
child mortality [4–8]. In contrast, inactivated vaccines including
diphtheria–tetanus–pertussis (DTP) vaccine may  increase all-cause
child mortality [9–11]. The nonspeciﬁc effects are often most
marked in females [2,8,10–12]. Most ﬁndings from low-income
countries relate to all-cause mortality. However, nonspeciﬁc effects
of vaccinations on the incidence of infectious diseases and admis-
sion rates have been reported from both low-income [13–17] and
high-income countries [18]. Recently, we found that the rate of
admissions related to infections and particularly lower respiratory
infections was  reduced for Danish children following vaccination
with the live MMR  vaccine against measles, mumps, and rubella
[19].
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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One of the most common causes of acute lower respiratory tract
nfections in infants is respiratory syncytial virus (RSV) [20–22].
orldwide, an estimated 33.8 million new cases occur each year
eading to 3.4 million hospital admissions of children under 5 years
f age [21]. A study from Guinea-Bissau found that BCG vaccina-
ion reduced the risk of severe RSV infection [16]. The aim of the
resent study was to examine the association between MMR  vac-
ine and the rate of hospital contacts resulting from RSV infection
n a high-income setting. In the study period, the Danish recom-
endations were to administer MMR  (Enders Edmonston, Jeryl
ynn, and Wistar RA 27/3) at 15 months of age after three doses
f the inactivated vaccine against diphtheria, tetanus, pertussis
acellular), polio, and Haemophilus inﬂuenzae type b (DTaP-IPV-Hib)
ecommended at 3, 5 and 12 months of age (see Supplementary
ig. 1). The prespeciﬁed hypothesis was that children most recently
accinated with MMR  have a lower rate of RSV hospital contact
ompared with children vaccinated most recently with the third
ose of DTaP-IPV-Hib (DTaP-IPV-Hib3).
. Material and methods
The Danish Civil Registration System was established in 1968
nd all Danish residents are assigned a unique personal identiﬁca-
ion number [23]. The personal identiﬁcation number is used by all
anish national registers and was used to link the registers for the
resent study.
.1. Vaccination register
In Denmark, all recommended childhood vaccinations are
dministered free-of-charge by the general practitioner (GP). For
he purpose of reimbursement, the GPs report all vaccinations to
he counties and from the counties the data are transferred to
he Danish National Health Service Register [24]. Based on this
nformation we  created a database of childhood vaccinations. Most
hildhood vaccinations were registered in a child’s name, but occa-
ionally childhood vaccinations were registered in a parent’s name
5.7%), particularly for young infants who only received their own
edical card after they had been named [25]. The recommended
hildhood vaccinations were only reimbursed by the counties for
ersons below 18 years of age. Childhood vaccinations registered to
n adult can therefore be assumed to have been administered to a
hild and we assigned such vaccinations to that adult’s child, which
as closest to the scheduled age of that vaccine. Vaccinations are
nly registered on a weekly basis. We  coded date of vaccination as
ednesday of the registered week of vaccination.
.2. RSV-database
Information on RSV-related hospital contacts was  obtained from
he Danish nationwide RSV-database, which was established for
esearch purposes by collection of information from the 18 Danish
aboratories testing for RSV among patients at the Danish hospi-
als, described in detail elsewhere [26]. The RSV-database covers
he period 1 January 1996 to 1 June 2003 were RSV was  examined
y ELISA or immunoﬂuorescence. During this period, all admitted
hildren with symptoms consistent with RSV were tested for RSV
o facilitate isolation of RSV cases from other admitted children to
educe the risk of transmission. In children born in Denmark and
egistered in the Danish Civil Registration System, the incidence
ates of hospital contacts with RSV were 25.2, 27.5, 16.0, and 6.8
er 1000 person years among the age groups less than 6 weeks,
 weeks-6 months, 6–14 months and 14–24 months, respectively.
e only included information on children born on 1 January 19973 (2015) 237–245
and onwards, because the vaccination schedule changed consider-
ably from 1996 to 1997.
2.3. Other register information
The Danish Civil Registration System contains information on
vital status and emigration which we used to deﬁne inclusion date
and follow-up periods [23]. It was also possible to obtain infor-
mation about the composition of each child’s household, and age
and country of birth of the parents. The Danish Medical Birth Reg-
ister contains information about birth weight, mode of delivery,
gestational age, and maternal smoking in pregnancy [27]. The Dan-
ish National Patient Register contains information about discharge
diagnoses [28]; we  used this register to obtain information on other
types of hospital contacts, including accidents and chronic dis-
eases. We  obtained information on household equivalence income
[29], maternal education [30], and public childcare from Statistics
Denmark.
2.4. Design
The study was  designed as a cohort study with retrospective
identiﬁcation of children born in Denmark during 1 January 1997
and 31 March 2002 and who  were alive and living in Denmark at
14 months of age. In the main analysis we  only included children
who had followed the recommended vaccination schedule for the
ﬁrst three vaccination visits by receiving DTaP-IPV-Hib1 before 4
months of age, DTaP-IPV-Hib2 before 6 months of age, and DTaP-
IPV-Hib3 before 13 months of age. The purpose of this selection was
to include children who resemble each other with respect to deter-
minants of vaccination and thereby reduce bias. Further details of
the inclusion are given in Fig. 1. Follow-up was stopped at 2 years
of age since oral polio vaccine (OPV) was  scheduled at 2 years of
age until July 1, 2001 (see Supplementary Fig. 1). The Danish Data
Protection Agency approved the study.
2.5. Statistical methods
To describe determinants of MMR  vaccination, we  estimated the
risk ratios (RRs) of being MMR-vaccinated at 16 months and 2 years
of age according to different covariates using Poisson regression
with robust variance [31].
To estimate incidence-rate-ratios (IRRs) and 95% conﬁdence
intervals (CIs) of RSV hospital contact according to most recent
vaccination we used Cox proportional hazard regression analysis.
Hence, the children changed vaccination status from DTaP-IPV-
Hib3 to MMR  on the date of MMR  vaccination. We included all RSV
hospital contacts, so one child could have several RSV hospital con-
tacts. To minimize the risk that the same episode of RSV infection
counted as two  hospital contacts we deﬁned the duration of one
RSV infection to be 14 days based on the expected maximal period
of shedding [32]. These 14 days were excluded from the count of
person years.
We used age as the underlying timescale of the Cox regression
model and stratiﬁed by date of birth such that cases were only
compared with children born on the same date and at the same
age; hence, we  controlled completely for any potential confound-
ing from age, season, and calendar year. Furthermore, the model
was adjusted for: sex, birth weight in grams (≤2000, 2001–2500,
2501–3000, 3001–3500, 3501–4000, 4001–4500, or >4500), gesta-
tional age (<37 weeks or ≥37 weeks of gestation), caesarean section
(no or yes), number of admissions for any cause between 1 month
of age and date of DTaP-IPV-Hib3 vaccination (none, one, two, or
≥three), admission for any cause from date of DTaP-IPV-Hib3 vac-
cination until 14 months of age (no or yes), maternal age at birth
of the child in years (≤19, 20–24, 25–29, 30–34, 35–39, or ≥40),
S. Sørup et al. / Vaccine 3
Fig. 1. Flowchart of the cohort. Abbreviations: RSV respiratory syncytial virus;
DTaP-IPV-Hib vaccination against diphtheria tetanus pertussis (acellular) polio
and Haemophilus inﬂuenzae type b; MMR  vaccination against measles mumps  and
rubella. In the parentheses, number of hospital contacts related to RSV from 14
months and until date of censoring for the children included in the study or
until 2 years of age for the children excluded from the study. a DTaP-IPV or Hib
alone (N = 17,882; 63.0%), not recommended combination of vaccines (N = 5348;
18.8%), fourth dose of DTaP-IPV-Hib (N = 3371; 11.9%), whole cell pertussis vaccine
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gN = 1011; 3.6%), OPV (N = 435; 1.5%), booster dose against diphtheria and tetanus
N  = 252; 0.9%), vaccine against hepatitis B (N = 87; 0.3%), and second dose of MMR
N  = 10; 0.0%). b Children receiving MMR  before DTaP-IPV-Hib3 were excluded.
arental place of birth (Denmark, Denmark-Foreign, or Foreign),
dult composition of the household (two adults, single parent, or
o parents), other children in the household (no or yes) and the
ime-varying variable chronic diseases (no or yes) coded accord-
ng to Kristensen et al., 2012 [33]. In additional analyses described
n the supplementary appendix further adjustment was  made for
aternal smoking in pregnancy, childcare, household income, and
aternal education.
.5.1. Interactions
Nonspeciﬁc effects of vaccines have previously been found to
nteract with sex and vitamin A supplementation [2,3]; other inter-
ctions might also be important. For this reason and to assess the
eneralizability of the results, we introduced interaction terms3 (2015) 237–245 239
between MMR  and dichotomised forms of the variables adjusted
for in the main analysis. The interaction terms were introduced in
the model one at a time and statistical signiﬁcance was  examined
with Wald test statistics.
2.5.2. Sensitivity
The assumption of proportional hazards between vaccination
groups was  evaluated by Schoenfeld residuals and no violation was
detected. We  examined if the effect of MMR  was immediate by
splitting the time period with MMR  at 30 days after MMR  vaccina-
tion. In addition we  examined for trend in the association according
to time since MMR  vaccination. The stability of the results was
examined by continuing follow-up until 3 years of age. In a sub-
group analysis, we  excluded children who had been admitted to
hospital with RSV before inclusion in the study to limit the poten-
tial effect of immunity to RSV. We  examined the generalizability of
the results by using a cohort which also included the children who
had not received the ﬁrst three doses of DTaP-IPV-Hib on time.
We do not believe that accidents are related to vaccination and
we therefore performed an analysis in which the outcome was acci-
dents registered at emergency room visits to check for possible
registration bias in our data material.
All analyses were performed in Stata 12.
3. Results
A total of 168,511 children were followed until the ﬁrst of the
following events: age 2 years (N = 129,333; 76.8%), 1 June 2003
(N = 25,475; 15.1%), administration of other vaccines than the ﬁrst
MMR (mainly OPV) (N = 13,370; 7.9%), migration (N = 296; 0.2%),
death (N = 31; 0.0%), unknown whereabouts for the Danish author-
ities (N = 4; 0.0%), and uncertainty about vaccinations for twins
(N = 2; 0.0%).
Overall 60.6% were vaccinated with MMR  by 16 months of age
and 91.8% at 2 years of age. There was little variation in the like-
lihood of being MMR-vaccinated, but children of single parents,
younger mothers, and children who  lived together with other chil-
dren were less likely to be MMR-vaccinated, particularly at 16
months of age (Table 1).
In 128,588 person years of follow-up 888 RSV hospital con-
tacts occurred (rate, 6.8/1000 person years); 886 children had one
RSV hospital contact each, while one child had two  RSV hospital
contacts during follow-up. The rate of RSV hospital contact accord-
ing to the vaccination status and age are given in Supplementary
Table 1. The median duration of RSV hospital contacts was  3 days
(inter quartile range, 2–5 days) in both DTaP-IPV-Hib3 and MMR-
vaccinated children.
Compared with children having DTaP-IPV-Hib3 as the most
recent vaccination, having MMR  as the most recent vaccination
was associated with a reduced rate of RSV hospital contacts (IRR,
0.75; 95% CI, 0.63–0.89; Table 2); the adjusted IRR was 0.78 (95%
CI, 0.66–0.93; Table 2). Further adjustment for maternal smoking
in pregnancy, childcare, household income, and maternal educa-
tion did not alter the results (Supplementary Table 3). In males,
the adjusted IRR of RSV hospital contacts for MMR  compared
with DTaP-IPV-Hib3 as the most recent vaccine was  0.74 (95% CI,
0.60–0.92), while the adjusted IRR for females was  0.84 (95% CI,
0.66–1.06; P Interaction, 0.42; Table 3). Also, none of the other
examined interactions were statistically signiﬁcant (Table 3).
The main results of the sensitivity analyses are given here; fur-
ther data is available on request. In the ﬁrst month after MMR
vaccination, the adjusted IRR for MMR  compared with DTaP-IPV-
Hib3 was 0.97 (95% CI, 0.76–1.24) but this changed signiﬁcantly
after one month to an adjusted IRR of 0.70 (95% CI, 0.58–0.85).
There was  a signiﬁcant trend for lower IRRs with longer time since
240
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Table 1
Distribution of most recent vaccine and risk ratios of being MMR-vaccinated at 16 months and 2 years of age according to background factors.
Characteristics 16 months of age 2 years of age
DTaP-IPV-Hib3% (N)a MMR  % (N)a Adjusted RRb (95%-CI) P valuec DTaP-IPV-Hib3% (N)a MMR  % (N)a Adjusted RRb (95%-CI) P valuec
Sex
Male 39.7% (33,700) 60.3% (51,136) 1 (Ref) .03 8.3% (6486) 91.7% (71,693) 1 (Ref) .10
Female  39.1% (32,328) 60.9% (50,369) 1.01 (1.00–1.02) 8.0% (6147) 92.0% (70,357) 1.00 (1.00–1.01)
Birth  weight, gram
≤2000 40.8% (834) 59.2% (1208) 1.02 (0.98–1.06) .01 8.0% (152) 92.0% (1738) 1.01 (0.99–1.02) .44
2001–2500  39.5% (2027) 60.5% (3107) 1.02 (1.00–1.05) 8.3% (396) 91.7% (4378) 1.00 (0.99–1.01)
2501–3000 38.3% (7978) 61.7% (12,856) 1.02 (1.01–1.04) 8.2% (1568) 91.8% (17,664) 1.00 (1.00–1.01)
3001–3500 39.5% (21,049) 60.5% (32,298) 1 (Ref) 8.2% (4043) 91.8% (45,178) 1 (Ref)
3501–4000 39.4% (22,254) 60.6% (34,200) 1.01 (1.00–1.02) 8.2% (4264) 91.8% (47,878) 1.00 (1.00–1.01)
4001–4500 40.1% (9634) 59.9% (14,377) 1.01 (0.99–1.02) 8.0% (1781) 92.0% (20,395) 1.01 (1.00–1.01)
>4500  39.4% (2252) 60.6% (3,459) 1.03 (1.00–1.05) 8.2% (429) 91.8% (4819) 1.01 (1.00–1.01)
Gestational age, weeks
<37 40.3% (3465) 59.7% (5139) 0.99 (0.96–1.01) .18 7.8% (622) 92.2% (7366) 1.01 (1.00–1.02) .04
≥37 39.4%  (62,563) 60.6% (96,366) 1 (Ref) 8.2% (12,011) 91.8% (134,684) 1 (Ref)
Caesarean section
No 39.5% (56,015) 60.5% (85,886) 1 (Ref) .60 8.2% (10,755) 91.8% (120,192) 1 (Ref) .53
Yes  39.1% (10,013) 60.9% (15,619) 1.00 (0.99–1.01) 7.9% (1878) 92.1% (21,858) 1.00 (1.00–1.01)
Chronic  diseases
No 39.3% (64,154) 60.7% (98,899) 1 (Ref) .03 8.1% (12,242) 91.9% (138,144) 1 (Ref) .40
Yes  41.8% (1874) 58.2% (2606) 0.97 (0.95–1.00) 9.1% (391) 90.9% (3906) 1.00 (0.99–1.01)
Number  of admissions between 1 month of age and date of DTaP-IPV-Hib3 vaccination
None 39.1% (55,540) 60.9% (86,521) 1 (Ref) <.001 8.0% (10,439) 92.0% (120,777) 1 (Ref) <.001
One  40.8% (7858) 59.2% (11,393) 0.98 (0.97–0.99) 9.1% (1617) 90.9% (16,127) 0.99 (0.98–0.99)
Two  42.5% (1747) 57.5% (2367) 0.96 (0.93–0.99) 10.3% (392) 89.7% (3400) 0.98 (0.97–0.99)
Three  or more 41.9% (883) 58.1% (1224) 0.98 (0.94–1.02) 9.6% (185) 90.4% (1746) 0.99 (0.98–1.00)
Admission from date of DTaP-IPV-Hib3 vaccination until 14 months of age
No  39.3% (64,073) 60.7% (98,879) 1 (Ref) <.001 8.1% (12,212) 91.9% (138,262) 1 (Ref) .001
Yes  42.7% (1955) 57.3% (2626) 0.95 (0.92–0.97) 10.0% (421) 90.0% (3788) 0.98 (0.97–0.99)
Maternal age at birth of the child, years
≤19 41.4% (1027) 58.6% (1452) 0.94 (0.91–0.98) <.001 11.9% (277) 88.1% (2043) 0.95 (0.94–0.97) <.001
20–24  37.1% (8509) 62.9% (14,411) 1.01 (1.00–1.02) 8.9% (1858) 91.1% (19,077) 0.98 (0.98–0.99)
25–29  38.1% (24,434) 61.9% (39,708) 1.01 (1.00–1.02) 7.5% (4443) 92.5% (54,593) 1.00 (0.99–1.00)
30–34 40.7% (22,732) 59.3% (33,069) 1 (Ref) 8.0% (4132) 92.0% (47,519) 1 (Ref)
35–39  42.0% (8231) 58.0% (11,357) 0.99 (0.98–1.01) 9.1% (1673) 90.9% (16,635) 0.99 (0.99–1.00)
≥40  42.1% (1095) 57.9% (1508) 0.99 (0.95–1.02) 10.3% (250) 89.7% (2183) 0.98 (0.96–0.99)
Parental place of birth
Denmark 39.2% (55,129) 60.8% (85,372) 1 (Ref) .004 8.2% (10,583) 91.8% (119,060) 1 (Ref) <.001
Denmark and foreign 40.5% (5539) 59.5% (8150) 0.98 (0.96–0.99) 8.4% (1063) 91.6% (11,629) 1.00 (0.99–1.00)
Foreign  40.2% (5360) 59.8% (7983) 1.01 (0.99–1.02) 8.0% (987) 92.0% (11,361) 1.01 (1.01–1.02)
Adult  composition of the household
Two adults 39.2% (61,640) 60.8% (95,795) 1 (Ref) <.001 7.9% (11,517) 92.1% (133,767) 1 (Ref) <.001
Single  parent 43.5% (4293) 56.5% (5573) 0.92 (0.91–0.94) 11.9% (1089) 88.1% (8088) 0.96 (0.95–0.97)
No  parents 40.9% (95) 59.1% (137) 1.03 (0.92–1.15) 12.2% (27) 87.8% (195) 0.98 (0.93–1.03)
Other  children in the household
No 34.9% (27,558) 65.1% (51,327) 1 (Ref) <.001 6.7% (4892) 93.3% (67,715) 1 (Ref) <.001
Yes  43.4% (38,470) 56.6% (50,178) 0.87 (0.86–0.88) 9.4% (7741) 90.6% (74,335) 0.97 (0.96–0.97)
Abbreviations: RR—risk ratio; MMR,  vaccination against measles, mumps, and rubella.
a The number of children do not add to the total number of children in the study, because some children were censored before the speciﬁed age.
b RR of being MMR  vaccinated at the speciﬁed age estimated by Poisson regression with robust variance and adjusted for all variables in the table.
c P values for the test of the association between the speciﬁed variable and vaccination status.
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Table  2
Incidence and incidence-rate-ratios of RSV hospital contact according to vaccination status.
Characteristics RSV hospital contacts per 1000
person years (RSV hospital
contacts/person yearsa)
Unadjusted IRRb (95%-CI) P Valuec Adjusted IRRd (95%-CI) P Valuec
Vaccination status
DTaP-IPV-Hib3 8.9 (320/35,995) 1 (Ref) .001 1 (Ref) .006
MMR  6.1 (568/92,593) 0.75 (0.63–0.89) 0.78 (0.66–0.93)
Abbreviations: RSV—respiratory syncytial virus; IRR—incidence-rate-ratio; DTaP-IPV-Hib3—vaccination with the third dose against diphtheria, tetanus, pertussis (acellular),
polio,  and Haemophilus inﬂuenzae type b; MMR,  vaccination against measles, mumps, and rubella.
a The distribution of person years for each category indicates the demographic features of the included children.
b Cox proportional hazards model with age as underlying time and stratiﬁed by date of birth thereby controlling for age and season.
c P values for the test of the association between the most recent vaccine and RSV hospital contacts.
d Cox proportional hazards model with age as underlying time, stratiﬁed by date of birth and adjusted for sex, birth weight, gestational age, caesarean section, chronic
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MR  vaccination (Table 4). In the sensitivity analysis in which
he children were followed to 3 years of age, an additional 129
ases of RSV hospital contacts were included and the estimate was
nchanged (adjusted IRR, 0.78; 95% CI, 0.66–0.93). The adjusted
RR of RSV hospital contact was 0.75 (95% CI, 0.63–0.90) when the
243 children who had been admitted with RSV before 14 months
f age were excluded. The results were also stable when all chil-
ren were included in the analysis irrespective of whether they
ad DTaP-IPV-Hib at the recommended ages (adjusted IRR, 0.79;
5% CI, 0.71–0.89).
There was no statistically signiﬁcant association between MMR
accination and emergency room visits resulting from accidents
adjusted IRR, 1.02; 95% CI, 0.98–1.06).
. Discussion
As hypothesised children who had received MMR  as their most
ecent vaccine had a lower rate of RSV hospital contacts compared
ith children who had DTaP-IPV-Hib3 as their most recent vacci-
ation. The association was only apparent from 1 month after MMR
accination. The association was similar for females and males and
id not vary signiﬁcantly according to any other background fac-
ors.
The main analyses of the present study included only children
ho had been vaccinated on time with DTaP-IPV-Hib to limit the
ossibility for confounding by factors related both to delayed vac-
ination and RSV hospital contact. There were too few RSV hospital
ontacts among children reversing the sequence of DTaP-IPV-Hib3
nd MMR  to perform an analysis in this group. It is important to
mphasize that the statistical model had age in days as the underly-
ng time scale securing elimination of any potential confounding by
ge by comparing the incidence of RSV hospital contacts between
hildren of the exact same age but with different vaccination sta-
us. Inclusion of a wide range of additional potential confounders
id not change the main estimate appreciably, indicating that con-
ounding was limited in the present study.
Since there was no association between MMR  vaccination and
ccidents, it seems unlikely that the association between MMR  vac-
ination and RSV hospital contacts can be explained by a bias in
ealth-seeking behavior.
Vaccinations were registered by GPs to obtain reimbursement;
his provides an economic incentive to report all vaccines [24].
owever, there might have been some underreporting of vaccines
34] and travel vaccines are not reimbursed and therefore not
eported [24], but we believe travel vaccines are limited before
wo years of age. Any misclassiﬁcation or underreporting of MMR
accinations would bias the estimates toward no association. The
utcome was RSV detected by ELISA or immunoﬂuorescence and
ncluded in the RSV database, which cover 96% of RSV hospitalination, admission from date of DTaP-IPV-Hib3 vaccination until 14 months of age,
old, and other children in the household (the IRR estimates for these variables are
contacts in Denmark [26]. RSV tests performed by ELISA or
immunoﬂuorescence are not as speciﬁc and sensitive as tests per-
formed by PCR [35] indicating that some misclassiﬁcation is present
in the current study. However, there is no reason to believe that the
sensitivity and speciﬁcity is affected by vaccination status; any mis-
classiﬁcation would bias the results toward no association. There
was a minimum of loss to follow-up because of the high quality of
the Danish population-based registries [23].
Our previous observation of reduction in the rate of all-cause
lower respiratory infections following MMR  vaccination [19] can
now partly be explained by a reduced rate of RSV hospital con-
tacts. However, reduction in hospital contacts related to bacterial
pathogens might also be important; a British self-controlled case-
series study reported the risk of lobar pneumonia to be reduced
0–90 days following MMR  vaccination [36]. In a similarly designed
study of premature children from the US, the risk of wheezing lower
respiratory disease in the ﬁrst 30 days following MMR  vaccination
was reduced compared with 45–90 days after MMR  vaccination
[37]. These studies indicate a short-lived association. However, in
the present study the association between MMR  vaccination and
RSV hospital contacts was only present from 30 days after MMR
vaccination and continued throughout the third year of life.
In contrast to studies from West Africa of measles vaccina-
tion [38,39], we did not ﬁnd any statistically signiﬁcant interaction
between MMR  vaccination and sex. MMR  was  associated with sig-
niﬁcant reduction in RSV hospital contacts in boys but not in girls.
Boys have a higher risk of severe RSV infection [40,41] as also
seen in the present study; therefore there is greater statistical
power to detect differences in boys. Furthermore, MMR  vaccina-
tion may  beneﬁt boys more because of their higher risk of severe
RSV infection. Also, there are numerous differences between high
and low-income settings that might interact with the nonspeciﬁc
and sex-differential effects of vaccinations, including family size,
nutritional status, micronutrient supplementation, sex-differential
access to care, the presence of atopic disease, exposure to infections
in public child care institutions, and genetic differences.
The present study suggests that the MMR  vaccine may  have ben-
eﬁcial nonspeciﬁc effects by reducing the rate of hospital contacts
related to RSV in a high-income setting. Only the most severe cases
of RSV are cared for at the hospital, so the reduction in hospital con-
tacts could be related to a reduction in the severity of RSV infection,
enhanced resistance to RSV infection or both. The ﬁnding contra-
dicts the current perception of vaccines as an intervention with a
disease-speciﬁc effect only. Our observation might be interpreted
as a chance ﬁnding or a ﬁnding resulting from uncontrolled con-
founding of factors related to delay in vaccination and the risk of
RSV hospital contact. However, there were hardly any difference
in characteristics between children who were and were not MMR-
vaccinated at 16 and 24 months of age (Table 1). Furthermore, if
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Table 3
Results for two-way-interactions between vaccination status and dichotomised forms of the variables included in the main analysis.
Characteristics RSV hospital contacts per 1000 person
years (RSV hospital contacts/person years)
Unadjusted IRRa (95%-CI) Adjusted IRRb (95%-CI)
Female
DTaP-IPV-Hib3 7.7 (136/17,637) 1 (Ref) 1 (Ref)
MMR  5.8 (265/45,774) 0.82 (0.65–1.04) 0.84 (0.66–1.06)
Male
DTaP-IPV-Hib3 10.0 (184/18,358) 1 (Ref) 1 (Ref)
MMR  6.5 (303/46,819) 0.70 (0.57–0.87) 0.74 (0.60–0.92)
P  interactionc .28 .42
No  other children in the household
DTaP-IPV-Hib3 8.5 (132/15,580) 1 (Ref) 1 (Ref)
MMR  6.0 (270/44,896) 0.78 (0.61–0.99) 0.82 (0.65–1.04)
Other children in the household
DTaP-IPV-Hib3 9.2 (188/20,415) 1 (Ref) 1 (Ref)
MMR  6.2 (298/47,696) 0.74 (0.60–0.91) 0.76 (0.61–0.94)
P  interactionc .70 .57
No  single parenthood
DTaP-IPV-Hib3 8.7 (294/33,604) 1 (Ref) 1 (Ref)
MMR  5.9 (519/87,445) 0.74 (0.62–0.89) 0.77 (0.64–0.92)
Single parenthood
DTaP-IPV-Hib3 10.9 (26/2391) 1 (Ref) 1 (Ref)
MMR  9.5 (49/5148) 0.96 (0.59–1.57) 1.00 (0.61–1.63)
P  interactionc .30 .30
Only Danish born parents
DTaP-IPV-Hib3 9.7 (294/30,157) 1 (Ref) 1 (Ref)
MMR  6.4 (502/77,870) 0.72 (0.60–0.86) 0.75 (0.63–0.90)
At  least one parent born outside Denmark
DTaP-IPV-Hib3 4.5 (26/5838) 1 (Ref) 1 (Ref)
MMR  4.5 (66/14,723) 1.11 (0.69–1.77) 1.12 (0.70–1.80)
P  interactionc .08 .10
Maternal age <30 years
DTaP-IPV-Hib3 8.9 (168/18,871) 1 (Ref) 1 (Ref)
MMR  6.3 (313/50,078) 0.76 (0.61–0.94) 0.79 (0.64–0.98)
Maternal age ≥30 years
DTaP-IPV-Hib3 8.9 (152/17,124) 1 (Ref) 1 (Ref)
MMR  6.0 (255/42,514) 0.74 (0.59–0.93) 0.77 (0.62–0.97)
P  Interaction c .86 .88
Normal birth weight (>2500 g)
DTaP-IPV-Hib3 8.5 (294/34,484) 1 (Ref) 1 (Ref)
MMR  5.9 (522/88,670) 0.75 (0.63–0.90) 0.79 (0.66–0.94)
Low  birth weight (≤2500 g)
DTaP-IPV-Hib3 17.2 (26/1511) 1 (Ref) 1 (Ref)
MMR  11.7 (46/3923) 0.69 (0.42–1.13) 0.73 (0.44–1.22)
P  interactionc .71 .79
Term (gestational age≥37 weeks)
DTaP-IPV-Hib3 8.6 (293/34,173) 1 (Ref) 1 (Ref)
MMR  5.8 (512/87,914) 0.74 (0.62–0.88) 0.77 (0.64–0.92)
Premature (gestational age<37 weeks)
DTaP-IPV-Hib3 14.8 (27/1822) 1 (Ref) 1 (Ref)
MMR  12.0 (56/4679) 0.87 (0.54–1.40) 0.94 (0.58–1.52)
P  interactionc .53 .42
No  caesarean section
DTaP-IPV-Hib3 8.5 (260/30,582) 1 (Ref) 1 (Ref)
MMR  5.6 (441/78,714) 0.72 (0.60–0.87) 0.75 (0.62–0.90)
Caesarean section
DTaP-IPV-Hib3 11.1 (60/5413) 1 (Ref) 1 (Ref)
MMR  9.2 (127/13,879) 0.88 (0.63–1.22) 0.94 (0.67–1.31)
P  interactionc .25 .21
No  chronic diseases
DTaP-IPV-Hib3 8.6 (301/34,985) 1 (Ref) 1 (Ref)
MMR  5.9 (528/90,110) 0.74 (0.62–0.89) 0.77 (0.65–0.93)
Chronic diseases
DTaP-IPV-Hib3 18.8 (19/1010) 1 (Ref) 1 (Ref)
MMR  16.1 (40/2483) 0.90 (0.51–1.57) 0.94 (0.53–1.67)
P  interactionc .52 .50
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Table  3 (Continued)
Characteristics RSV hospital contacts per 1000 person
years (RSV hospital contacts/person years)
Unadjusted IRRa (95%-CI) Adjusted IRRb (95%-CI)
No admissions between 1 month of age and date of DTaP-IPV-Hib3 vaccination
DTaP-IPV-Hib3 7.4 (225/30,285) 1 (Ref) 1 (Ref)
MMR  4.9 (385/78,784) 0.72 (0.59–0.88) 0.74 (0.60–0.90)
Admissions during 1 month of age and date of DTaP-IPV-Hib3 vaccination
DTaP-IPV-Hib3 16.6 (95/5710) 1 (Ref) 1 (Ref)
MMR  13.3 (183/13,809) 0.86 (0.65–1.12) 0.89 (0.68–1.17)
P  interactionc .28 .23
No  admission from date of DTaP-IPV-Hib3 vaccination until 14 months of age
DTaP-IPV-Hib3 8.5 (298/34,936) 1 (Ref) 1 (Ref)
MMR  5.8 (523/90,193) 0.74 (0.62–0.88) 0.76 (0.64–0.91)
Admission from date of DTaP-IPV-Hib3 vaccination until 14 months of age
DTaP-IPV-Hib3 20.8 (22/1059) 1 (Ref) 1 (Ref)
MMR  18.7 (45/2400) 1.06 (0.62–1.80) 1.12 (0.66–1.92)
P  interactionc .19 .16
Abbreviations: RSV—respiratory syncytial virus; IRR—incidence-rate-ratio; DTaP-IPV-Hib3—vaccination with the third dose against diphtheria, tetanus, pertussis (acellular),
polio,  and Haemophilus inﬂuenzae type b; MMR,  vaccination against measles, mumps, and rubella.
a Cox proportional hazards model with age as underlying time and stratiﬁed by date of birth thereby controlling for age and season.
b Cox proportional hazards model with age as underlying time, stratiﬁed by date of birth and adjusted for sex, birth weight, gestational age, caesarean section, chronic
diseases, number of admissions between 1 month of age and date of DTaP-IPV-Hib3 vaccination, admission from date of DTaP-IPV-Hib3 vaccination until 14 months of age,
maternal age at birth of the child, parental place of birth, adult composition of the household, and other children in the household.
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ther  variables; for example, if the IRR for MMR  differs between females and males
he beneﬁcial effect of MMR  resulted from confounding, the same
eneﬁt should have been observed in the ﬁrst month after vacci-
ation. Several randomized trials from low-income countries have
ocumented that nonspeciﬁc effects of vaccines are indeed possible
1]. In one of these trials from Guinea-Bissau [5] measles vaccine
as particularly effective in reducing hospital admissions related
o respiratory infections [17].
Nonspeciﬁc effects of vaccines have often been dismissed as bio-
ogically implausible. However, immunological studies have shown
hat a pathogen encounter may  alter the subsequent resistance
oward other infections [2,3]. These changes can occur at the level
f the innate immune system; for example, BCG may  enhance
he nonspeciﬁc innate resistance through epigenetic reprogramm-
ng of monocytes [42]. Numerous animal studies have shown that
athogens can also induce nonspeciﬁc alterations of the adap-
ive immune system, through cross-reacting T-cell epitopes [43].
otably, measles virus, mumps  virus, and RSV all belong to the
amily paramyxoviridae and one study in mice found T-cell cross
eactivity between these viruses [44] and a study in children found
hat prior RSV infection was related to higher antibody titres against
easles, mumps, and rubella following vaccination with MMR  [45].
urther studies on the biological mechanisms are clearly needed,
n particular whether antigen-speciﬁc responses or non-speciﬁc
able 4
esults according to time since MMR  vaccination.
Characteristics RSV hospital contacts per 1000 person
years (RSV hospital contacts/person ye
Vaccination status
DTaP-IPV-Hib3 8.9 (320/35,989) 
Days  since MMR  vaccination
0–30 8.7 (105/12,107) 
31–90 7.0 (164/23,469) 
91–210 5.6 (239/42,461) 
>210  4.1 (60/14,546) 
P  trend 
bbreviations: RSV—respiratory syncytial virus; IRR—incidence-rate-ratio; DTaP-IPV-Hib
olio,  and Haemophilus inﬂuenzae type b; MMR,  vaccination against measles, mumps, and
a Cox proportional hazards model with age as underlying time and stratiﬁed by date of
b Cox proportional hazards model with age as underlying time, stratiﬁed by date of b
iseases, number of admissions between 1 month of age and date of DTaP-IPV-Hib3 vacc
aternal age at birth of the child, parental place of birth, adult composition of the househes. This corresponds to testing if the IRR for MMR  varies between categories of the
inﬂammatory/innate mechanisms are more important for the pro-
tection we  observed in the present study.
The current WHO  recommendations do not consider nonspe-
ciﬁc effects of vaccines. However, WHO’s Strategic Advisory Group
of Experts has recently recommended further research into non-
speciﬁc effects of vaccines [46]. Ideally, the age schedule for
vaccinations should be evaluated in trials testing both the speciﬁc
effect and the nonspeciﬁc effects on overall morbidity and mortal-
ity. In high-income countries it might reduce the risk of hospital
contacts and reduce health care costs to lower the age of MMR
vaccination or introduce an additional dose of MMR  vaccination
at an earlier age, particularly bearing in mind that the greatest
burden of RSV occurs in children below 12 months of age [21].
If conﬁrmed in further studies in high-income settings, the non-
speciﬁc beneﬁcial effect of MMR  vaccination could be used as an
additional incentive for parents to have their children vaccinated
on time.
In conclusion, the present nationwide cohort study showed that
the rate of RSV hospital contact was reduced in Danish children who
had received MMR  rather than DTaP-IPV-Hib3 as their most recent
vaccination. The ﬁnding has major public health implications. Fur-
ther studies are needed to test this observation and to examine
whether earlier administration of MMR  might be beneﬁcial.
ars)
Unadjusted IRRa (95%-CI) Adjusted IRRb (95%-CI)
1 (Ref) 1 (Ref)
0.98 (0.77–1.25) 1.01 (0.79–1.28)
0.78 (0.62–0.97) 0.82 (0.65–1.03)
0.62 (0.49–0.79) 0.64 (0.50–0.82)
0.40 (0.27–0.60) 0.43 (0.29–0.64)
<0.001 <0.001
3—vaccination with the third dose against diphtheria, tetanus, pertussis (acellular),
 rubella.
 birth thereby controlling for age and season.
irth and adjusted for sex, birth weight, gestational age, caesarean section, chronic
ination, admission from date of DTaP-IPV-Hib3 vaccination until 14 months of age,
old, and other children in the household.
2 cine 3
F
t
R
p
t
g
l
r
A
c
d
d
t
a
r
d
i
a
A
t
h
A
f
2
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[44 S. Sørup et al. / Vac
unding
This work was  supported by the Health Foundation [2009B132
o S.S.]; Rosalie Petersens Foundation [to S.S.]; Danish National
esearch Foundation [DNRF108 to S.S., C.S.B., L.G.S. and H.R.]; Euro-
ean Research Council [ERC-2009-StG, grant agreement no. 243149
o C.S.B.]; and the Novo Nordisk Foundation [research professorship
rant to P.A.]. The funders had no role in study design; in the col-
ection, analysis and interpretation of data; in the writing of the
eport; and in the decision to submit the article for publication
uthor’s contributions
S.S. conceptualized and designed the study, acquired the vac-
ination and confounder data, analyzed and interpreted the data,
rafted the initial manuscript. C.S.B. and P.A. conceptualized and
esigned the study, interpreted the data and reviewed and revised
he manuscript. L.G.S. conceptualized and designed the study,
cquired the RSV hospital contact data, interpreted the data,
eviewed and revised the manuscript. H.R. conceptualized and
esigned the study, acquired the vaccination and confounder data,
nterpreted the data, reviewed and revised the manuscript, All
uthors read and approved the ﬁnal manuscript.
cknowledgements
The authors thank Tyra G Krause from Department of Infec-
ious Disease Epidemiology, Statens Serum Institut, Denmark, for
er valuable comments on the draft for this article.
Conﬂict of interest statement
All authors have no conﬂicts of interest to disclose.
ppendix A. Supplementary data
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
014.07.110.
eferences
[1] Aaby P, Whittle H, Stabell Benn C. Vaccine programmes must consider their
effect on general resistance. BMJ  2012;344:e3769 [10.1136/bmj.e3769].
[2] Flanagan KL, van Crevel R, Curtis N, Shann F, Levy O, Optimmunize N.
Heterologous (“nonspeciﬁc”) and sex-differential effects of vaccines: epidemi-
ology, clinical trials, and emerging immunologic mechanisms. Clin Infect Dis
2013;57:283–9 [10.1093/cid/cit209].
[3] Benn CS, Netea MG,  Selin LK, Aaby P. A small jab—a big effect: non-
speciﬁc immunomodulation by vaccines. Trends Immunol 2013;34:431–9
[10.1016/j.it.2013.04.004].
[4] Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H. Non-speciﬁc
beneﬁcial effect of measles immunisation: analysis of mortality studies from
developing countries. BMJ  1995;311:481–5 [10.1136/bmj.311.7003.481].
[5] Aaby P, Martins CL, Garly ML,  Bale C, Andersen A, Rodrigues A, et al. Non-
speciﬁc effects of standard measles vaccine at 4.5 and 9 months of age
on  childhood mortality: randomised controlled trial. BMJ  2010;341:c6495
[10.1136/Bmj.C6495].
[6] Aaby P, Roth A, Ravn H, Napirna BM,  Rodrigues A, Lisse IM,  et al. Random-
ized trial of BCG vaccination at birth to low-birth-weight children: beneﬁcial
nonspeciﬁc effects in the neonatal period? J Infect Dis 2011;204:245–52
[10.1093/infdis/jir240].
[7] Biering-Sorensen S, Aaby P, Napirna BM,  Roth A, Ravn H, Rodrigues A, et al.
Small randomized trial among low-birth-weight children receiving bacillus
Calmette–Guerin vaccination at ﬁrst health center contact. Pediatr Infect Dis J
2012;31:306–8 [10.1097/INF.0b013e3182458289].
[8] Shann F. The non-speciﬁc effects of vaccines. Arch Dis Child 2010;95:662–7
[10.1136/adc.2009.157537].
[9] Aaby P, Jensen H, Gomes J, Fernandes M,  Lisse IM. The introduc-
tion of diphtheria–tetanus–pertussis vaccine and child mortality in rural
Guinea-Bissau: an observational study. Int J Epidemiol 2004;33:374–80
[10.1093/ije/dyh005].
10] Aaby P, Benn CS, Nielsen J, Lisse IM,  Rodrigues A, Ravn H. Testing the hypoth-
esis that diphtheria-tetanus-pertussis vaccine has negative non-speciﬁc and
sex-differential effects on child survival in high-mortality countries. BMJ Open
2012;2:e000707 [10.1136/bmjopen-2011-000707].
[3 (2015) 237–245
11] Aaby P, Ravn H, Roth A, Rodrigues A, Lisse IM,  Diness BR, et al. Early diphtheria-
tetanus-pertussis vaccination associated with higher female mortality and
no difference in male mortality in a cohort of low birthweight children: an
observational study within a randomised trial. Arch Dis Child 2012;97:685–91
[10.1136/archdischild-2011-300646].
12] Aaby P, Benn CS. Non-speciﬁc and sex-differential effects of routine vaccines:
what evidence is needed to take these effects into consideration in low-income
countries? Hum Vaccin 2011;7:120–4 [10.4161/hv.7.1.13848].
13] Veirum JE, Sodemann M, Biai S, Jakobsen M,  Garly ML,  Hedegaard K,
et  al. Routine vaccinations associated with divergent effects on female and
male mortality at the paediatric ward in Bissau, Guinea-Bissau. Vaccine
2005;23:1197–204 [10.1016/j.vaccine.2004.02.053].
14] Valentiner-Branth P, Perch M,  Nielsen J, Steinsland H, Garly ML,  Fischer TK,
et  al. Community cohort study of Cryptosporidium parvum infections: sex-
differential incidences associated with BCG and diphtheria-tetanus-pertussis
vaccinations. Vaccine 2007;25:2733–41 [10.1016/j.vaccine.2006.01.035].
15] Rodrigues A, Fischer TK, Valentiner-Branth P, Nielsen J, Steinsland H, Perch M,
et  al. Community cohort study of rotavirus and other enteropathogens: are
routine vaccinations associated with sex-differential incidence rates? Vaccine
2006;24:4737–46 [10.1016/j.vaccine.2006.03.033].
16] Stensballe LG, Nante E, Jensen IP, Kofoed PE, Poulsen A, Jensen H, et al. Acute
lower respiratory tract infections and respiratory syncytial virus in infants
in  Guinea-Bissau: a beneﬁcial effect of BCG vaccination for girls community
based case-control study. Vaccine 2005;23:1251–7 [10.1016/j.vaccine.2004.
09.006].
17] Martins CL, Benn CS, Andersen A, Bale C, Schaltz-Buchholzer F, Do VA, et al.
A  randomized trial of a standard dose of Edmonston–Zagreb measles vaccine
given at 4.5 months of age: effect on total hospital admissions. J Infect Dis
2014;209:1731–8 [10.1093/infdis/jit804].
18] Sorup S, Villumsen M,  Ravn H, Benn CS, Sorensen TI, Aaby P, et al. Smallpox
vaccination and all-cause infectious disease hospitalization: a Danish register-
based cohort study. Int J Epidemiol 2011;40:955–63 [10.1093/ije/dyr063].
19] Sorup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Live vaccine against
measles, mumps, and rubella and the risk of hospital admissions for nontar-
geted infections. JAMA 2014;311:826–35 [10.1001/jama.2014.470].
20] Garcia-Garcia ML,  Calvo C, Pozo F, Villadangos PA, Perez-Brena P, Casas I. Spec-
trum of respiratory viruses in children with community-acquired pneumonia.
Pediatr Infect Dis J 2012;31:808–13 [10.1097/INF.0b013e3182568c67].
21] Nair H, Nokes DJ, Gessner BD, Dherani M,  Madhi SA, Singleton RJ, et al.
Global burden of acute lower respiratory infections due to respiratory syn-
cytial virus in young children: a systematic review and meta-analysis. Lancet
2010;375:1545–55 [10.1016/S0140-6736(10)60206-1].
22] Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syn-
cytial virus epidemiology: a developed country perspective. Respir Med
2002;96(Suppl B):S1–7 [10.1053/rmed.2002.1294].
23] Pedersen CB. The Danish Civil Registration System. Scand J Public Health
2011;39:22–5 [10.1177/1403494810387965].
24] Andersen JS, Olivarius NDF, Krasnik A. The Danish National Health Service
Register. Scand J Public Health 2011;39:34–7 [10.1177/1403494810394718].
25] Pedersen PA, Hollnagel H, Olivarius NF, Reusch S, Sorensen M,  Thorsen H.
Individual registration of children in the national health service. New pos-
sibilities for epidemiological research in primary health care. Ugeskr Laeger
1999;161:6351–4.
26] Stensballe LG, Kristensen K, Nielsen J, Aaby P. Diagnosis coding in The Danish
National Patient Registry for respiratory syncytial virus infections. Scand J Infect
Dis  2005;37:747–52 [10.1080/00365540510012107].
27] Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med  Bull
1998;45:320–3.
28] Lynge E, Sandegaard JL, Rebolj M.  The Danish National Patient Register. Scand
J  Public Health 2011;39:30–3 [10.1177/1403494811401482].
29] Baadsgaard M,  Quitzau J. Danish registers on personal income and transfer pay-
ments. Scand J Public Health 2011;39:103–5 [10.1177/1403494811405098].
30] Jensen VM,  Rasmussen AW.  Danish Education Registers. Scand J Public Health
2011;39:91–4 [10.1177/1403494810394715].
31] Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional
studies: an empirical comparison of models that directly estimate the preva-
lence ratio. BMC  Med  Res Methodol 2003;3:21 [10.1186/1471-2288-3-21].
32] Okiro EA, White LJ, Ngama M,  Cane PA, Medley GF, Nokes DJ. Duration of shed-
ding of respiratory syncytial virus in a community study of Kenyan children.
BMC  Infect Dis 2010;10:15 [10.1186/1471-2334-10-15].
33] Kristensen K, Hjuler T, Ravn H, Simoes EA, Stensballe LG. Chronic diseases,
chromosomal abnormalities, and congenital malformations as risk factors for
respiratory syncytial virus hospitalization: a population-based cohort study.
Clin Infect Dis 2012;54:810–7 [10.1093/cid/cir928].
34] Wojcik OP, Simonsen J, Molbak K, Valentiner-Branth P. Validation of
the  5-year tetanus, diphtheria, pertussis and polio booster vaccination
in the Danish childhood vaccination database. Vaccine 2013;31:955–9
[10.1016/j.vaccine.2012.11.100].
35] Henrickson KJ, Hall CB. Diagnostic assays for respiratory syncytial virus disease.
Pediatr Infect Dis J 2007;26:S36–40 [10.1097/INF.0b013e318157da6f].
36] Stowe J, Andrews N, Taylor B, Miller E. No evidence of an increase of bacterial
and  viral infections following measles, mumps  and rubella vaccine. Vaccine
2009;27:1422–5 [10.1016/j.vaccine.2008.12.038].
37] Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F, team V.S.D. Wheez-
ing lower respiratory disease and vaccination of premature infants. Vaccine
2011;29:7611–7 [10.1016/j.vaccine.2011.08.022].
cine 3
[
[
[
[
[
[
[
[S. Sørup et al. / Vac
38] Aaby P, Garly ML,  Bale C, Martins C, Jensen H, Lisse I, et al. Survival of
previously measles-vaccinated and measles-unvaccinated children in an emer-
gency situation: an unplanned study. Pediatr Infect Dis J 2003;22:798–805
[10.1097/01.inf.0000083821.33187.b5].
39] Desgrees du LA, Pison G, Aaby P. Role of immunizations in the recent decline
in  childhood mortality and the changes in the female/male mortality ratio in
rural  Senegal. Am J Epidemiol 1995;142:643–52.
40] Sommer C, Resch B, Simoes EA. Risk factors for severe respiratory syncy-
tial  virus lower respiratory tract infection. Open Microbiol J 2011;5:144–54
[10.2174/1874285801105010144].
41] Stensballe LG, Kristensen K, Simoes EA, Jensen H, Nielsen J, Benn CS, et al. Atopic
disposition, wheezing, and subsequent respiratory syncytial virus hospitaliza-
tion in Danish children younger than 18 months: a nested case-control study.
Pediatrics 2006;118:e1360–8 [10.1542/peds.2006-0907].
[3 (2015) 237–245 245
42] Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille
Calmette-Guerin induces NOD2-dependent nonspeciﬁc protection from rein-
fection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA
2012;109:17537–42 [10.1073/pnas.1202870109].
43] Welsh RM,  Che JW,  Brehm MA,  Selin LK. Heterologous immunity between
viruses. Immunol Rev 2010;235:244–66 [10.1111/j.0105-2896.2010.00897.x].
44] Ziola B, Smith RH. T cell cross-reactivity among viruses of the paramyxoviridae.
Viral Immunol 1987;1:111–9.
45] Ziola B, Karvonen B, Stewart J. Prior infection by respiratory syncytial virus or
parainﬂuenza viruses augments virus-speciﬁc IgG responses induced by the
measles/mumps/rubella vaccine. Viral Immunol 1994;7:205–14.
46] Meeting of the Strategic Advisory Group of Experts on immuniza-
tion, April 2014—conclusions and recommendations. Wkly Epidemiol Rec
2014;89:221–36.
